🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

314 results for “cells” Clear

  1. Auto-CD34+ cells

    LISATA THERAPEUTICS, INC.

    Chronic Myocardial Ischemia

    phase 3 mab completed

    1 trial

  2. CLS2901C (human [allogeneic] chondrocyte sheets)

    CellSeed Europe Ltd

    Osteoarthritis of the Knee

    phase 3 mab active

    1 trial

  3. Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion

    Vertex Pharmaceuticals (Australia) Pty.

    Sickle Cell Disease, Transfusion dependent thalassemia

    phase 3 small molecule active

    1 trial

  4. Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN, FILGRASTIM, PLERIXAFOR

    Vertex Pharmaceuticals (Australia) Pty.

    Transfusion-Dependent-Thalassemia

    phase 3 small molecule active

    1 trial

  5. Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN, FILGRASTIM, PLERIXAFOR

    Vertex Pharmaceuticals (Australia) Pty.

    Transfusion-dependent β-thalassemia (TDT)

    phase 3 small molecule active

    1 trial

  6. Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, PLERIXAFOR, BUSULFAN

    Vertex Pharmaceuticals (Australia) Pty.

    Severe sickle cell disease (SCD)

    phase 3 small molecule active

    1 trial

  7. Cytokine-Induced Killer Cells

    Sun Yat-sen University

    Carcinoma, Hepatocellular

    phase 3 mab completed

    1 trial

  8. Dexamethasone Tablets BP 2.0mg, Fortecortin® 2 mg Tabletten, Lenalidomide Accord 15 mg hard capsules, CARVYKTI 3.2 × 10^6 – 1.0 × 10^8 cells dispersion for infusion, Lenalidomide Mylan 5 mg hard capsules, Lenalidomide Mylan 20 mg hard capsules, VELCADE 3.5 mg powder for solution for injection, Lenalidomide Mylan 20 mg hard capsules, Lenalidomide Accord 10 mg hard capsules, Lenalidomide Accord 2.5 mg hard capsules, FLUDARABINE , Lenalidomide Mylan 15 mg hard capsules, Lenalidomide Accord 10 mg hard capsules

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  9. Expanded autologous adipose-derived adult stem cells (eASCs)

    Takeda

    Complex Perianal Fistula

    phase 3 small molecule terminated

    1 trial

  10. Libmeldy 2-10 x 10^6 cells/mL dispersion for infusion

    Orchard Therapeutics (Netherlands) B.V.

    Metachromatic Leukodystrophy (MLD)

    phase 3 small molecule active

    1 trial

  11. Libmeldy 2-10 x 10^6 cells/mL dispersion for infusion

    Orchard Therapeutics (Netherlands) B.V.

    Metachromatic Leukodystrophy (MLD) is an autosomal recessive disorder caused by mutations

    phase 3 small molecule active

    1 trial

  12. Mesenchymal Stromal Cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Graft-Versus-Host Disease

    phase 3 mab active

    1 trial

  13. NurOwn® (MSC-NTF cells)

    BRAINSTORM CELL THERAPEUTICS INC.

    Amyotrophic Lateral Sclerosis (ALS)

    phase 3 mab completed

    2 trials

  14. PLERIXAFOR, Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN, FILGRASTIM

    Vertex Pharmaceuticals (Australia) Pty.

    Transfusion-dependent β-thalassemia (TDT), Severe sickle cell disease (SCD)

    phase 3 small molecule active

    1 trial

  15. Pomalidomide, Imnovid 3 mg hard capsules, Imnovid 1 mg hard capsules, Imnovid 2 mg hard capsules, Imnovid 4 mg hard capsules, Pomalidomide, Pomalidomide, DARZALEX 1800 mg solution for injection, Imnovid 3 mg hard capsules, BORTEZOMIB, Imnovid 2 mg hard capsules, FLUDARABINE , CARVYKTI 3.2 × 10^6 – 1.0 × 10^8 cells dispersion for infusion, Pomalidomide, Imnovid 4 mg hard capsules, Dexamethasone Tablets BP 2.0mg, Fortecortin® 2 mg Tabletten, Imnovid 1 mg hard capsules, CYCLOPHOSPHAMIDE , Dexamethason 4 mg JEN

    Janssen-Cilag International N.V.

    Relapsed and Lenalidomide-Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  16. Suspension of autologous mononuclear cells separated from bone marrow aspirate

    The George Institute

    diabetic foot syndrome, lower limb ischemia

    phase 3 small molecule active

    1 trial

  17. Vedolizumab Placebo

    Takeda

    Hematopoietic Stem Cells

    phase 3 small molecule completed

    1 trial

  18. YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion, Revlimid 20 mg hard capsules, Bendamustine 100mg Powder for Concentrate for Solution for Infusion, Vincristine Sulfate 1 mg/ml Solution for Injection or Infusion, Doxorubicin Teva 2 mg/ml Concentrate for Solution for Infusion, Endoxana Injection 1000 mg Powder for Solution for Injection, Prednisolone 5 mg Soluble Tablets, MabThera 500 mg concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  19. A Phase I First-in-Human Dose Escalation Trial to Evaluate the Safety and Efficacy of ARI-HER2 (HER2BBz CAR-T Cells) in Patients with HER2Positive Advanced Breast Cancer

    The George Institute

    Patients with HER2Positive Advanced Breast Cancer

    phase 2 other active

    1 trial

  20. ADCETRIS 50 mg powder for concentrate for solution for infusion

    Takeda

    Hodgkin lymphoma (HL) - Hodgkin lymphoma (HL), a neoplasm of lymphoid tissue which is histopathologically defined by the presence of malignant Hodgkin Reed-Sternberg (HRS) cells in a background of inflammatory cells. The proposed pediatric study has been designed to evaluate brentuximab vedotin as a component of a multiagent frontline chemotherapy regimen in patients with advanced stage, newly diagnosed HL, here defined as Stage III and Stage IV and a ≥50 Lansky Play-Performance or Karnofsky Performance Status.

    phase 2 small molecule active

    1 trial

  21. ADCT-602

    ADC Therapeutics SA

    Blasts 5 Percent or More of Bone Marrow Nucleated Cells

    phase 2 mab terminated

    1 trial

  22. ALDESLEUKIN , TIL cells

    Disc Medicine

    Ovarian carcinoma

    phase 2 small molecule active

    1 trial

  23. ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS

    Lxo Ireland Designated Activity Company

    Sars-CoV2

    phase 2 small molecule completed

    1 trial

  24. ARI-0001, YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion

    Disc Medicine

    relapsed/refractory Non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources